Souhaitez-vous accéder aux communiqués récents ?

Manassas, VA, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Notal Vision, Inc. reported today that the latest data on its investigational home-based optical coherence tomography (OCT) and how the service can be...

ALPHARETTA, Ga, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...

BEDFORD, Mass. and SHANGHAI, China, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Frontera Therapeutics, a global clinical-stage biotechnology company that seeks to develop novel and best-in-class gene therapy...

- Suprachoroidal CLS-AX Resulted in Favorable Safety Data, Durability and Biologic Effect Over 6 Months in Treatment-Experienced Anti-VEGF Sub-Responders - - 67% of Extension Study Participants Went...

New York, USA, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Age-Related Macular Degeneration Market Overview: According to a Comprehensive Research Report by Market Research Future (MRFR), “Age-Related...

REDWOOD CITY, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY) (“Graybug” or the “Company”), a clinical-stage biopharmaceutical company focused historically on...

- Primary Safety Endpoint Achieved at all Timepoints with All Doses Well-Tolerated and No Treatment Related or Serious Adverse Events - - Cohorts 3 and 4 Demonstrated Promising Signs of Durability,...

New York, USA, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Wet AMD Clinical Trials Pipeline Analysis Featuring 70+ Key Companies by DelveInsight DelveInsight’s Wet AMD pipeline analysis depicts a robust...

KIN001 has synergistic antiviral, anti-inflammatory activity, and anti-fibrotic mechanismsPhase 2 trials of KIN001 in hospitalized and ambulatory COVID-19 patients ongoingInterim data from Phase 2...

Financing to be drawn in tranchesFinancing will enable Kinarus to advance the clinical development of KIN001 Basel, Switzerland, August 22, 2022. Kinarus Therapeutics Holding AG (SIX: KNRS)...